Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
NCT00976677
Terminated
This randomized phase II trial studies how well carboplatin, paclitaxel, and bevacizumab work with or without erlotinib hydrochloride in treating non-smokers with advanced non-small cell lung cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2014
Locations: The Medical Center of Aurora, Aurora, Colorado +107 locations
Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Register for Updates
Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC
NCT00544648
Terminated
RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) may make tumor cells more sensitive to radiation therapy. Giving nab-paclitaxel together with radiation therapy and carboplatin may kill more tumor cells. PURPOSE: This phase I/II tri... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2014
Locations: Purchase Cancer Group - Paducah, Paducah, Kentucky +5 locations
Conditions: Lung Cancer
Register for Updates
Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer
NCT00003050
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy plus paclitaxel in treating patients with stage IIB or stage III breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2014
Locations: USC/Norris Comprehensive Cancer Center, Los Angeles, California +1 locations
Conditions: Breast Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer
NCT00003449
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of dexamethasone plus paclitaxel and gemcitabine in treating patients with platinum-resistant recurrent ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/20/2014
Locations: USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California
Conditions: Ovarian Cancer
Register for Updates
Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
NCT00507429
Terminated
The purpose of the study is to determine the safety and efficacy of combretastatin combined with paclitaxel and carboplatin in the treatment of anaplastic thyroid cancer (ATC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2014
Locations: USC/Norris Comprehensive Cancer Center, Los Angeles, California +40 locations
Conditions: Anaplastic Thyroid Cancer
Register for Updates
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer
NCT00021320
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with or without radiation therapy in treating patients who have esophageal cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2014
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Esophageal Cancer
Register for Updates
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
NCT00119262
Completed
This phase II trial is studying how well giving bevacizumab together with combination chemotherapy works in treating patients who have undergone surgery for breast cancer that has spread to the lymph nodes. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2014
Locations: Eastern Cooperative Oncology Group, Boston, Massachusetts
Conditions: Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Register for Updates
Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer
NCT00614484
Terminated
The purpose of this study is to determine the effectiveness of proton beam radiotherapy combined with chemotherapy for treatment of locally advanced non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2014
Locations: Loma Linda University Medical Center, Loma Linda, California
Conditions: Locally Advanced Non-Small Cell Lung Cancer
Register for Updates
TAXUS PERSEUS Workhorse
NCT00484315
Completed
The purpose of the TAXUS PERSEUS Workhorse trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo atherosclerotic lesions of up to 28 mm in length in native coronary arteries of 2.75 mm to 4.0 mm diameter.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2014
Locations: Baptist Medical Center Princeton, Birmingham, Alabama +89 locations
Conditions: Coronary Artery Disease
Register for Updates
TAXUS PERSEUS Small Vessel
NCT00489541
Completed
The purpose of the TAXUS PERSEUS Small Vessel trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo atherosclerotic lesions of up to 20 mm in length in native coronary arteries of ≥ 2.25 mm to \< 2.75 mm diameter.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2014
Locations: Medical Center East, Birmingham, Alabama +27 locations
Conditions: Coronary Artery Disease
Register for Updates
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
NCT02044601
Withdrawn
The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of onartuzumab that can be given with erlotinib and standard chemoradiation (paclitaxel and carboplatin) to patients with NSCLC. The goal of Phase II is to learn if onartuzumab plus erlotinib and chemoradiation can help to control NSCLC. The safety of this drug will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2014
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
NCT01235897
Completed
The purpose of this study is to test the safety and safest highest dose of an investigational drug called MK-2206 when given in combination with paclitaxel and trastuzumab in patients with Human Epidermal growth factor Receptor 2 (HER2)-overexpressing solid tumor malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2014
Locations: University of California, San Francisco, San Francisco, California
Conditions: Advanced Solid Tumors, Tumors, Cancer
Register for Updates